These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 16639731)

  • 1. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
    Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
    Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
    Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W
    J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
    Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
    Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
    Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
    N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.